Attenuation of nitrate tolerance and oxidative stress by an angiotensin II receptor blocker in patients with coronary spastic angina

Circulation

Volumn 108, Issue 12, 2003, Pages 1446-1450

  Hirai, Nobutaka ^a   Kawano, Hiroaki ^a   Yasue, Hirofumi ^b   Shimomura, Hideki ^a   Miyamoto, Shinzo ^a   Soejima, Hirofumi ^a   Kajiwara, Ichiro ^d   Sakamoto, Tomohiro ^a   Yoshimura, Michihiro ^d   Nakamura, Hajime ^b   Yodoi, Junji ^c   Ogawa, Hisao ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b Kumamoto Aging Research Institute   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d NONE

Author keywords

Angiotensin; Nitroglycerin; Ultrasonics; Vasodilation

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; GLYCERYL TRINITRATE; NITRATE; THIOREDOXIN;

ADULT; AGED; ANGINA PECTORIS; ARTERY DIAMETER; ARTICLE; BLOOD LEVEL; BRACHIAL ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY SPASM; DISEASE MARKER; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ULTRASOUND;

ADMINISTRATION, CUTANEOUS; AGED; ANGINA PECTORIS; BENZIMIDAZOLES; BIOLOGICAL MARKERS; BRACHIAL ARTERY; CORONARY VASOSPASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FEMALE; HEADACHE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; NITRATES; NITROGLYCERIN; OXIDATIVE STRESS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; TETRAZOLES; THIOREDOXIN; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 0141839064     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000089092.61590.A8     Document Type: Article

References (34)

1. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med. 1998;338:520-531.
2. Elkayam U. Nitrates in the treatment of congestive heart failure. Am J Cardiol. 1996:77:41C-51C.
3. Glasser SP. Prospects for therapy of nitrate tolerance. Lancet. 1999;353: 1545-1546.
4. Munzel T, Kurz S, Heitzer T, et al. New insights into mechanisms underlying nitrate tolerance. Am J Cardiol. 1996;77:24C-30C.
5. Kurz S, Hink U, Nickenig G, et al. Evidence for a causal role of the rennin-angiotensin system in nitrate tolerance. Circulation. 1999:99:3181-3187.
6. Okumura K, Yasue H, Horio Y, et al. Multivessel coronary spasm in patients with variant angina: a study with intracoronary injection of acetylcholine. Circulation. 1988;77:535-542.
7. Pignoli P, Tremoli E, Poli A, et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 1986;74:1399-1406.
8. Nakamura H, Vaage J, Valen G, et al. Measurements of plasma glutaredoxin and thioredoxin in healthy volunteers and during open heart surgery. Free Radic Biol Med. 1998;24:1176-1186.
9. Kogaki H, Fujiwara Y, Yoshiki A, et al. Sensitive enzyme-linked immunosorbent assay for adult T-cell leukemia-derived factor and normal value measurement. J Clin Lab Anal. 1996;10:257-261.
10. Crandall LA, Leake CD, Loevenhart AS, et al. Acquired tolerance to and cross-tolerance between the nitrous and nitric acid esters and sodium nitrite in man. J Pharmacol Exp Ther. 1931;41:103-119.
11. Watanabe H, Kakihana M, Ohtsuka S, et al. Preventive effects of angiotensin-converting enzyme inhibitors on nitrate tolerance during continuous transdermal application of nitroglycerin in patients with chronic heart failure. Jpn Circ J. 1998;62:353-358.
12. Elkayam U, Johnson JV, Shotan A, et al. Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition. Circulation. 1999;99:2652-2657.
13. Mumbara T, Tayama S, Tabuchi T, et al. Effects of angiotensin-converting enzyme inhibitor alacepril in patients with stable effort angina during chronic isosorbide dinitrate treatment. Am J Cardiol. 1996;63:1159-1163.
14. Dupuis J, Lalonde G, Bichet D, et al. Captopril does not prevent nitroglycerin tolerance in heart failure. Can J Cardiol. 1990;6:281-286.
15. Dakak N, Makhoul N, Flugelman MY, et al. Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1990;66:608-613.
16. Parker JD, Parker JO. Effect of therapy with an angiotensin-converting enzyme inhibitor on hemodynamic and counterregulatory responses during continuous therapy with nitroglycerin. J Am Coll Cardiol. 1993;21:1445-1453.
17. Milone SD, Azevedo ER, Forster C, et al. The angiotensin II-receptor antagonist losartan does not prevent hemodynamic or vascular tolerance to nitroglycerin. J Cardiovasc Pharmacol. 1999;34:645-650.
18. Jeserich M, Munzel T, Pape L, et al. Absence of vascular tolerance in conductance vessels after 48 hours of intravenous nitroglycerin in patients with coronary artery disease. J Am Coll Cardiol. 1995;26:50-56
19. Yasue H, Kugiyama K. Coronary spasm: clinical latures and pathogenesis. Intern Med. 1997;36:760-765.
20. Kugiyama K, Ohgushi M, Sugiyama S, et al. Supersensitive dilator response to nitroglycerin but not to atrial natriuretic peptide in spastic coronary arteries in coronary spastic angina. Am J Cardiol. 1997;79:606-610.
21. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
22. Bassenge E, Fink N, Skalchkov M, et al. Dietary supplement with vitamin C prevents nitrate tolerance. J Clin Invest. 1998;102:67-71.
23. Watanabe H, Kakihana M, Ohtsuka S, et al. Randomized, double-blind, placebo-controlled study of vitamin E supplementation on attenuation of development of nitrate tolerance. Circulation. 1997;96:2545-2550.
24. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
25. Khaper N, Singal PK. Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats. Am Coll Cardiol. 2001;37:1461-1466.
26. Padi SS, Chopra K. Selective angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity. Pharmacol Res. 2002;45:413-420.
27. Wassmann S, Hilgers S, Laufs U, et al. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2002;22:1208-1212.
28. Arner ESJ, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem. 2002;67:6102-6109.
29. Nakamura H, Nakamura K, Yodoi J. Redox regulation of cellular activation. Ann Rev Immunol. 1997;15:351-369.
30. Shioji K, Kishimoto C, Nakamura H, et al. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation. 2002;106:1403-1409.
31. Nakamura H, De Rosa S, Roederer M, et al. Elevation of plasma thioredoxin levels in HIV-infected individuals. Int Immunol. 1996;8:603-611.
32. Huhner R, Hogemann AM, Sunzel M, et al. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens. 1997;11:S19-S25.
33. Fridman K, Andersson OK, Wysocki M, et al. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systematic and renal haemodynamics in hypertensive patients. Eur J Clin Pharmacol. 1998;54:497-501.
34. McClellan KJ, Goa KL. Candesartan cilexetil: a review of its use in essential hypertension. Drugs. 1998;56:847-869.